A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles Sonal GandhiMuriel BrackstoneThe Canadian National Neoadjuvant Breast Cancer Consortium Review Open access 28 February 2022 Pages: 1 - 20
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies Peter E. HallPeter Schmid Review 02 March 2022 Pages: 21 - 35
Three-year follow-up of de-escalated axillary treatment after neoadjuvant systemic therapy in clinically node-positive breast cancer: the MARI-protocol Ariane A. van LoevezijnMarieke E. M. van der NoordaaMarie-Jeanne T. F. D. Vrancken Peeters Preclinical study Open access 03 March 2022 Pages: 37 - 48
High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer Rongrong WuAnkit PatelKazuaki Takabe Preclinical study 06 March 2022 Pages: 49 - 63
Exosomal MMP-1 transfers metastasis potential in triple-negative breast cancer through PAR1-mediated EMT Yihui ZhuZhonghua TaoXichun Hu Preclinical study 07 March 2022 Pages: 65 - 81
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study Robert S. MillerStella MokiouKatherine Baria Clinical trial Open access 22 February 2022 Pages: 83 - 94
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial Mario CamponeMichelino De LaurentiisMiguel Martín Clinical trial 25 February 2022 Pages: 95 - 103
Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings Jayesh ChavdaArpan MishraMuktesh Khandare Clinical trial 05 March 2022 Pages: 105 - 110
Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast Huiqing JiaPeng ZhaoChengqin Wang Clinical trial Open access 08 March 2022 Pages: 111 - 120
Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer Tan Hong QiOng Hiok HianAi3 Clinical Trial 09 March 2022 Pages: 121 - 138
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey Solveig K. SmedslandKathrine F. VandraasKristin V. Reinertsen Epidemiology Open access 28 February 2022 Pages: 139 - 149
Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers Aswin ShanmugalingamKerry HitosNicholas K. Ngui Epidemiology 28 February 2022 Pages: 151 - 159
Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA M. A. A. RagusiB. H. M. van der VeldenS. G. Elias Epidemiology Open access 03 March 2022 Pages: 161 - 173
Trends in surgery and adjuvant treatment for early-stage breast cancer: a population-based study in Queensland, Australia Philippa YoulShoni PhilpotDavid E. Theile Epidemiology 07 March 2022 Pages: 175 - 185
The association between meat and fish intake by preparation methods and breast cancer in the Carolina Breast Cancer Study (CBCS) Omonefe O. OmofumaSusan E. SteckMelissa A. Troester Epidemiology 11 March 2022 Pages: 187 - 201
Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–2016 Erin J. Aiello BowlesCody RaminGretchen L. Gierach Epidemiology 11 March 2022 Pages: 203 - 216
Common founder BRCA2 pathogenic variants and breast cancer characteristics in Ethiopian Jews S. LiebermanR. Chen-ShtoyermanY. Goldberg Epidemiology 12 March 2022 Pages: 217 - 224
Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study Oliver William ScottSandar Tin TinRoss Lawrenson Epidemiology Open access 14 March 2022 Pages: 225 - 235
Comment on “Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis” Weihong NieHua DingXiao Zou Letter to the Editor 17 February 2022 Pages: 237 - 238
Radiotherapy, chemotherapy, and heart disease Chrissa Sioka Letter to the Editor 28 February 2022 Pages: 239 - 240
